Despite conventional wisdom, political uncertainty doesn’t necessarily pose acute risks to the healthcare sector.

The cost of prescription medicine is a constant strain for many Americans.

In small-cap markets, fundamental research is in short supply—and good environmental, social and governance (ESG) research is even scarcer.

Supply-chain disruptions are testing companies around the world.

The revolutionary technology of synthetic biology is poised to make a profound impact on the way a vast array of products are manufactured, from lab-grown meat to cosmetics to biodegradable packaging. Yet investors are paying relatively little attention to the huge business potential.